Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results

Retina

Volumn 30, Issue 7, 2010, Pages 1017-1024

  Parravano, Mariacristina ^a   Oddone, Francesco ^a   Tedeschi, Massimiliano ^a   Chiaravalloti, Adele ^a   Perillo, Loredana ^a   Boccassini, Barbara ^a   Varano, Monica ^a  

^a IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; RETINA; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; THICKNESS; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PERIMETRY; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 77954756852     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181cfd3c6     Document Type: Article

References (35)

1. Klein R. Epidemiology. In: Berger JW, Fine SL, Maguire MG, eds. Age-Related Macular Degeneration. St. Louis, MO: Mosby; 1999:31-55.
2. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-1624.
3. Friedman DS, O'Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122: 564-572.
4. Leibowitz HM, Krueger CE, Maunder LR, et al. The Framingham eye study monograph: an ophthalmologic and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in the general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980; 24:S335-S610.
5. D'Amico DJ. Diseases of the retina. N Engl J Med 1994;331: 95-105.
6. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993;115:783-791.
7. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one year results of 2 randomized clinical trials-TAP report 1. Treatment of age related macular degeneration with photodynamic therapy study group. Arch Ophthalmol 1999;117: 1329-1345.
8. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000;55: 15-35; discussion 35-36.
9. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
10. Chen Y,Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinitymatured Fab in complex with antigen. J Mol Biol 1999;293: 865-881.
11. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
12. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1432-1444.
13. Kaiser PK, Blodi BA, Shapiro H, Acharya NR; Marina Study Group. Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114: 1868-1875.
14. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
15. Prager F, Michels S, Simader C, Geitzenauer W, Schmidt- Erfurth U. Changes in retinal sensitivity in patients with neovascular age related macular degeneration after systemic bevacizumab (Avastin) therapy. Retina 2008;28:682-688.
16. Nussenblatt RB, Kaufman SC, Palestine AG, Davis MD, Ferris FL III. Macular thickening and visual acuity: measurement in patients with cystoid macular edema. Ophthalmology 1987;94: 1134-1139.
17. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-806.
18. Schneider U, Kuck H, InhoffenW, Kreissig I. Fundus-controlled microperimetry with the scanning laser ophthalmoscope in macular diseases [in German]. Klin Monbl Augenheilkd 1993; 203:212-218.
19. Varano M, Scassa C. Scanning laser ophthalmoscope micro perimetry. Semin Ophthalmol 1998;13:203-209.
20. Midena E, Radin PP, Pilotto E, Ghirlando A, Convento E, Varano M. Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to agerelated macular degeneration. A microperimetry study. Semin Ophthalmol 2004;19:55-61.
21. Schneider U, InhoffenW, Gelisken F, Kreissig I. Assessment of visual function in choroidal neovascularization with scanning laser microperimetry and simultaneous indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol 1996;234: 612-617.
22. Tezel TH, Del Priore LV, Flowers BE, et al. Correlation between scanning laser ophthalmoscope microperimetry and anatomic abnormalities in patients with subfoveal neovascularization. Ophthalmology 1996;103:1829-1836.
23. Parravano M, Oddone F, Tedeschi M, et al. Retinal functional changes measured by microperimetry in neovascular agerelated macular degeneration patients treated with ranibizumab. Retina 2009;29:329-334.
24. Ferris FL III, Kassof A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94: 91-96.
25. Rohrschneider K, Springer C, Bultmann S, Völcker HE. Microperimetry-comparison between themicro perimeter 1 and scanning laser ophthalmoscope-fundus perimetry. Am J Ophthalmol 2005;139:125-134.
26. Springer C, Bültmann S, Völcker HE, Rohrschneider K. Fundus perimetry with the Micro Perimeter 1 in normal individuals. Ophthalmology 2005;l12:848-854.
27. Fujii GY, de Juan E Jr, Sunness J, Humayun MS, Pieramici DJ, Chang TS. Patient selection for macular translocation surgery using the scanning laser ophthalmoscope. Ophthalmology 2002;109:1737-1744.
28. Puliafito CA, Hee MR, Lin CP, et al. Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995;102:217-229.
29. Chen FK, Patel PJ, Xing W, et al. Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease. Invest Ophthalmol Vis Sci 2009;50:3464-3472.
30. Andersen MV. Scanning laser ophthalmoscope microperimetry compared with Octopus perimetry in normal subjects. Acta Ophthalmol Scand 1996;74:135-139.
31. Midena E, ed. Perimetry and the Fundus. An Introduction to Microperimetry. Thorofare, NJ: Slack Inc; 2007:229-237.
32. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age related macular degeneration. Am J Ophthalmol 2007;143: 679-680.
33. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148:43-58.
34. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47:S253-S252.
35. Vujosevic S, Midena E, Pilotto E, Radin PP, Chiesa L, Cavarzeran F. Diabetic macular edema: correlation between micro perimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci 2006;47:3044-3051.